---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-144582"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:03:42.802296+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibikase enrolls first patient in Phase 3 PAH study of IKT-001

## Summary
- First patient enrolled in global pivotal Phase 3 IMPROVE-PAH trial (NCT07365332).
- Part A: ~140 patients, primary endpoint change in PVR at Week 24, double-blind placebo-controlled.
- Part B: ~346 patients, primary endpoint change in 6MWD at Week 24, seamless transition from Part A.
- Adaptive design includes a 12-week dose-titration phase; FDA confirmed study plan.
- Trial to be conducted at up to ~180 sites worldwide; NDA filing timeline accelerated.

## SEC filing metadata
- accession: 0001193125-26-144582
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526144582/0001193125-26-144582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526144582/d108350d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-144582
- JSON: https://secwatch.observer/filing/0001193125-26-144582.json
- Plain text: https://secwatch.observer/filing/0001193125-26-144582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.